OncoAssure, the NovaUCD-headquartered Irish medical diagnostics company has agreed an exclusive partnership with Illinois-based GoPath Diagnostics. Under the agreement, GoPath will hold the exclusive rights to provide the OncoAssureTM Prostate test in the US. Read More
SIGRID Therapeutics today announced the U.S. launch of Carb Fence™, the company’s flagship medical food powered by patented SiPore® technology. The launch represents a major commercialization milestone for SIGRID and the first market introduction of the clinically evaluated 9 g daily SiPore® protocol following more than 15 years of scientific development and clinical studies, including the SHINE study, one of the largest randomized controlled studies of its kind. Read More
Signum Surgical, the Galway-based medical technology company, has appointed Mark J Foley as chairman of the board. A highly accomplished medical device executive, Foley has decades of experience scaling innovative healthcare companies in the US and internationally. Read More
Mirai Medical announced that it secured approximately $8.4 million (€7.2 million) in funding from the Irish government. The Galway-based company earned its funding through the country’s Disruptive Technologies Innovation Fund (DTIF) Call 7 for its PIONEER technology — Pathology and Immuno-Oncology with Next-Generation Screening and Electroporation for Enhanced Response. Read More
OncoAssure, an Irish medtech company and a leading innovator in precision oncology diagnostics, today announced the signing of a research collaboration agreement with the Icahn School of Medicine at Mount Sinai, in New York, which will facilitate the performance of a new validation study utilising OncoAssure’s Prostate Cancer Test and curated clinical samples from Icahn School of Medicine at Mount Sinai. Read More
FDA Approves the ProVee System - the First of a New Generation of Prostatic Urethral Stents for Treatment of BPH. ProVerum Limited, a medical device company focused on innovative, safe and effective solutions for treating benign prostatic hyperplasia (BPH), today announced it has received FDA approval for its ProVee® System for BPH. FDA approval was supported by results from the ProVIDE study, a randomized, double-blind, sham-controlled trial evaluating the safety and effectiveness of the ProVee System in men with moderate-to-severe BPH. The study met all primary and secondary endpoints, demonstrating significant and durable symptom relief and improvements in urinary flow through [...]
Deciphex, a leader in AI-powered digital pathology, today announced the execution of a new €15 million investment from Claret Capital Partners, Europe's largest independent growth debt fund manager. This strategic financing will accelerate Deciphex's expansion in the United States and support the company's ambition to become the leading provider of histopathology reporting services in the UK by 2027. Read More
NovaUCD-based medtech OncoAssure has announced the launch of its OncoAssure Prostate Test in the US market, as well as plans to hold an investment round last year. The next-generation prognostic test is designed to support clinical decision-making for men diagnosed with localised prostate cancer, and helps to assess the risk of aggressive disease and disease recurrence. Read More
Cinclus Pharma Holding, a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of gastric acid-related diseases, has announced an agreement with Zentiva, a European pharmaceutical company, for the commercialisation and manufacturing of its lead asset, linaprazan glurate, in Europe. Read More
Signum Surgical, the medical technology company developing innovative solutions to treat colorectal diseases, is pleased to announce the appointment of Ms. Carol Burns as Chief Executive Officer. Ms. Burns’ appointment is a pivotal milestone for Signum, as the Company initiates commercialization of BioHealx, a first-of-its-kind medical device for the treatment of anal fistula, a painful and debilitating colorectal condition that affects one in 5,000 people worldwide. Read More
